Apexxnar®

APEXXNAR® is a 20-valent pneumococcal conjugate vaccine for adults that helps protect against the 20 Streptococcus pneumoniae serotypes included in the vaccine.1

APEXXNAR is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.1

Expanded for a new level of protection1,2

apexxnar

APEXXNAR adds 7 serotypes to Prevenar 13® (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]).1,2

 

References:

  1. APEXXNAR®. Summary of Product Characteristics.
  2. Prevenar 13. Summary of Product Characteristics.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Legal Category: S1A

PP-PNR-IRL-0006 Date of Preparation: July 2022